{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T15:34:53Z","timestamp":1783697693540,"version":"3.55.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"13","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.vaccine.2023.02.018","type":"journal-article","created":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T15:32:26Z","timestamp":1676043146000},"page":"2253-2260","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Six-month safety follow-up of an adjuvanted SARS-CoV-2 trimeric S-protein subunit vaccine (SCB-2019) in adults: A phase 2\/3, double-blind, randomized study"],"prefix":"10.1016","volume":"41","author":[{"given":"Romana","family":"Hosain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Aquino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Baccarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7075-9827","authenticated-orcid":false,"given":"Igor","family":"Smolenov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haijing","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole","family":"Verhoeven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7215-7635","authenticated-orcid":false,"given":"Branda","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yung","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Rubio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2023.02.018_b0005","unstructured":"GAVI. The COVID-19 vaccine race. Available from: https:\/\/www.gavi.org\/vaccineswork\/covid-19-vaccine-race\/ [accessed 20 June 2022]."},{"key":"10.1016\/j.vaccine.2023.02.018_b0010","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1056\/NEJMp2005630","article-title":"Developing Covid-19 Vaccines at Pandemic Speed","volume":"382","author":"Lurie","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2023.02.018_b0015","unstructured":"UNICEF. COVID-19 Market Dashboard. Available from: https:\/\/www.unicef.org\/supply\/covid-19-market-dashboard\/ [accessed 19 September 2022]."},{"key":"10.1016\/j.vaccine.2023.02.018_b0020","unstructured":"World Health Organization. Coronavirus dashboard. Available from: https:\/\/covid19.who.int\/\/ [accessed 19 Sep 2022]."},{"key":"10.1016\/j.vaccine.2023.02.018_b0025","first-page":"10","article-title":"A Narrative Review of COVID-19 Vaccines","author":"Eroglu","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2023.02.018_b0030","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1126\/science.abb8923","article-title":"Rapid COVID-19 vaccine development","volume":"368","author":"Graham","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2023.02.018_b0035","unstructured":"Law B, Sturkenboom M. D2.3 Priority list of Adverse Events of Special Interest: COVID-19. Available from: https:\/\/brightoncollaboration.us\/wp-content\/uploads\/2020\/06\/SPEAC_D2.3_V2.0_COVID-19_20200525_public.pdf\/ [accessed 31 May 2022]."},{"key":"10.1016\/j.vaccine.2023.02.018_b0040","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1016\/j.vaccine.2021.01.055","article-title":"Vaccine-associated enhanced disease: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data","volume":"39","author":"Munoz","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.02.018_b0045","unstructured":"The Brighton Collaboration. Safety Platform for Emergency Vaccines. Adverse Events of Special Interest (AESIs) for COVID-19 Vaccines Surveillance. Available from: https:\/\/brightoncollaboration.us\/wp-content\/uploads\/2021\/01\/COVID-19-updated-AESI-list.pdf\/ [accessed 10 June 2022]."},{"key":"10.1016\/j.vaccine.2023.02.018_b0050","unstructured":"AstraZeneca. Vaxveria Summary of Product Characteristics. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-product-information_en.pdf\/ [accessed 31 May 2022]."},{"key":"10.1016\/j.vaccine.2023.02.018_b0055","unstructured":"Janssen. Jcovden (previously COVID-19 Vaccine Janssen) Summary of Product Characteristics. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/jcovden-previously-covid-19-vaccine-janssen\/ [accessed 31 May 2022]."},{"key":"10.1016\/j.vaccine.2023.02.018_b0060","unstructured":"Moderna. Spikevax Summary of Product Characteristics. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/spikevax-previously-covid-19-vaccine-moderna-epar-product-information_en.pdf\/ [accessed 19 September 2022]."},{"key":"10.1016\/j.vaccine.2023.02.018_b0065","unstructured":"BioNTech\/Pfizer. Comirnaty COVID-19 mRNA Vaccine. Summary of Product Characteristics. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/comirnaty-epar-product-information_en.pdf\/ [accessed 31 May 2022]."},{"key":"10.1016\/j.vaccine.2023.02.018_b0070","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s12916-021-02059-5","article-title":"Evaluation of the safety profile of COVID-19 vaccines: a rapid review","volume":"19","author":"Wu","year":"2021","journal-title":"BMC Med"},{"key":"10.1016\/j.vaccine.2023.02.018_b0075","doi-asserted-by":"crossref","first-page":"e059223","DOI":"10.1136\/bmjopen-2021-059223","article-title":"Reports of myocarditis and pericarditis following mRNA COVID-19 vaccination: a systematic review of spontaneously reported data from the UK, Europe and the USA and of the scientific literature","volume":"12","author":"Lane","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.vaccine.2023.02.018_b0080","unstructured":"World Health Organization. Interim recommendations for use of the AZD1222 (ChAdOx1-S [recombinant]) vaccine against COVID19 developed by Oxford University and AstraZeneca: interim guidance, 10 February 2021. Available from: https:\/\/apps.who.int\/iris\/handle\/10665\/339477\/ [accessed 31 May 2022]."},{"key":"10.1016\/j.vaccine.2023.02.018_b0085","unstructured":"World Health Organization. Guidance for clinical case management of thrombosis with thrombocytopenia syndrome (TTS) following vaccination to prevent coronavirus disease (COVID-19). Available from: https:\/\/www.who.int\/publications\/i\/item\/WHO-2019-nCoV-TTS-2021.1\/ [accessed 31 May 2022]."},{"key":"10.1016\/j.vaccine.2023.02.018_b0090","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S0140-6736(21)01693-7","article-title":"Very rare thrombosis with thrombocytopenia after second AZD1222 dose: a global safety database analysis","volume":"398","author":"Bhuyan","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2023.02.018_b0095","unstructured":"World Health Organization. Statement of the WHO Global Advisory Committee on Vaccine Safety (GACVS) COVID-19 subcommittee on reports of Guillain-Barr\u00e9 Syndrome (GBS) following adenovirus vector COVID-19 vaccines. Available from: https:\/\/www.who.int\/news\/item\/26-07-2021-statement-of-the-who-gacvs-covid-19-subcommittee-on-gbs\/ [accessed 31 May 2022]."},{"key":"10.1016\/j.vaccine.2023.02.018_b0100","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s13223-021-00613-7","article-title":"Anaphylactic and nonanaphylactic reactions to SARS-CoV-2 vaccines: a systematic review and meta-analysis","volume":"17","author":"Alhumaid","year":"2021","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.vaccine.2023.02.018_b0105","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1001\/jamapediatrics.2022.0088","article-title":"Hypersensitivity Reactions to COVID-19 Vaccines-Identify High-risk Children and Vaccinate the Rest","volume":"176","author":"Fernandez-Davila","year":"2022","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.vaccine.2023.02.018_b0110","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.882972","article-title":"Vaccine-Associated Enhanced Disease and Pathogenic Human Coronaviruses","volume":"13","author":"Gartlan","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2023.02.018_b0115","first-page":"12","article-title":"Prospects for a safe COVID-19 vaccine","author":"Haynes","year":"2020","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.vaccine.2023.02.018_b0120","first-page":"95","article-title":"Cryo-EM structure of S-Trimer, a subunit vaccine candidate for COVID-19","author":"Ma","year":"2021","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2023.02.018_b0125","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/S0140-6736(21)00241-5","article-title":"Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial","volume":"397","author":"Richmond","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2023.02.018_b0130","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S0140-6736(22)00055-1","article-title":"Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial","volume":"399","author":"Bravo","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2023.02.018_b0135","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1016\/j.vaccine.2013.01.042","article-title":"Optimal approaches to data collection and analysis of potential immune mediated disorders in clinical trials of new vaccines","volume":"31","author":"Tavares Da Silva","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.02.018_b0140","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1007\/s40264-020-01002-6","article-title":"Assessing the Safety of COVID-19 Vaccines: A Primer","volume":"43","author":"Petousis-Harris","year":"2020","journal-title":"Drug Saf"},{"key":"10.1016\/j.vaccine.2023.02.018_b0145","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.15585\/mmwr.mm7032e4","article-title":"Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices - United States, July 2021","volume":"70","author":"Rosenblum","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2023.02.018_b0150","doi-asserted-by":"crossref","unstructured":"World Health Organization. COVID-19 subcommittee of the WHO Global Advisory Committee on Vaccine Safety (GACVS): updated statement regarding myocarditis and pericarditis reported with COVID-19 mRNA vaccines. Available from: https:\/\/www.who.int\/news\/item\/27-10-2021-gacvs-statement-myocarditis-pericarditis-covid-19-mrna-vaccines-updated\/ [accessed 01 June 2022].","DOI":"10.1007\/s40278-022-08352-8"},{"key":"10.1016\/j.vaccine.2023.02.018_b0155","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1093\/ehjqcco\/qcab090","article-title":"Myocarditis and pericarditis in adolescents after first and second doses of mRNA COVID-19 vaccines","volume":"8","author":"Foltran","year":"2022","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"10.1016\/j.vaccine.2023.02.018_b0160","unstructured":"Dulay AT. Spontaneous Abortion. Available from: https:\/\/www.msdmanuals.com\/professional\/gynecology-and-obstetrics\/abnormalities-of-pregnancy\/spontaneous-abortion\/ [accessed 07 June 2022]."},{"key":"10.1016\/j.vaccine.2023.02.018_b0165","unstructured":"Centers for Disease Control and Prevention. Underlying Medical Conditions Associated with Higher Risk for Severe COVID-19: Information for Healthcare Professionals. Available from: https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/hcp\/clinical-care\/underlyingconditions.html\/ [accessed 17 June 2022]."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23001445?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23001445?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:24:34Z","timestamp":1759404274000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X23001445"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":33,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S0264410X23001445"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.02.018","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Six-month safety follow-up of an adjuvanted SARS-CoV-2 trimeric S-protein subunit vaccine (SCB-2019) in adults: A phase 2\/3, double-blind, randomized study","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.02.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}